Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to…
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial…
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing…
HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced…
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in…
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating…
Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO) Lixte Biotechnology Holdings, Inc. PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE)…
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched…
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) --…